Article Per Year (5 Year)
p-Index From 2021 - 2026
3.298
P-Index
This Author published in this journals
All Journal Jurnal Ruas (Review of Urbanism and Architectural Studies) Indonesian Journal of Cancer Journal of Industrial Engineering Management Syntax Literate: Jurnal Ilmiah Indonesia Dinasti International Journal of Economics, Finance & Accounting (DIJEFA) Jurnal Kajian Ilmiah Quantitative Economics and Management Studies International Journal of Engineering, Science and Information Technology Arsitekno ETNIK : Jurnal Ekonomi dan Teknik Humantech : Jurnal Ilmiah Multidisiplin Indonesia Rumoh: Journal of Architecture Jurnal Lingkungan Binaan Indonesia Innovative: Journal Of Social Science Research International Journal of Accounting, Management, Economics and Social Sciences (IJAMESC) Jurnal Bisnis dan Ekonomi Jurnal Solusi Masyarakat Dikara
Bambang Karsono
RS. Kanker Dharmais
Religion Arts Humanities Astronomy Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Civil Engineering, Building, Construction & Architecture Computer Science & IT Control & Systems Engineering Decision Sciences, Operations Research & Management Earth & Planetary Sciences Economics, Econometrics & Finance Education Electrical & Electronics Engineering Energy Engineering Environmental Science Health Professions Industrial & Manufacturing Engineering Law, Crime, Criminology & Criminal Justice Library & Information Science Materials Science & Nanotechnology Mathematics Mechanical Engineering Physics Public Health Social Sciences Transportation Other

Published : 26 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Indonesian Journal of Cancer

 1 
Efficacy and Safety of In-Asia-Manufactured rhG-CSF 300 mcg As Primary Prophylaxis for Prevention of CHOP Chemotherapy-induced Severe Neutropenia in Elderly Patients with Lymphoma Non-Hodgkin Reksodiputro, Harryanto; Djoerban, Zubairi; Tambunan, Karmel L.; Sudoyo, Aru W.; Widjanarko, Abidin; Atmakusuma, Djumhana; Syafei, Syafrizal; Prayogo, Nugroho; Hukom, Ronald; Ranuhardy, Dody; Jack, Zakifman; Harsal, Asrul; -, Noorwati S; Karsono, Bambang; Effendi, Shufrie; Tadjoedin, Hilman
Indonesian Journal of Cancer Vol 3, No 1 (2009): Jan - Mar 2009
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (790.74 KB)

Abstract

Penelitian open-label, non-komparatif ini dilakukan untuk mengevaluasi efektivitas dan keamanan recombinant human G-CSF produksi Asia sebagai profilaksis primer dalam pencegahan neutropenia derajat berat pada pasien usia lanjut (>60 tahun) dengan limfoma non-Hodgkin (LNH) derajat sedang dan lanjut (stadium II,III,IV) yang mendapat terapi CHOP (siklofosfamid, doksorubisin, vinkristin). Profilaksis primer recombinant human G-CSF (rhG-CSF) produksi Asia dapat mengurangi median durasi neutropenia derajat 4 pada siklus sitostatistika ke-1 dan ke-2 menjadi tiga hari, sementara median durasi neutropenia derajat 3 pada siklus sitostistika ke-1 menjadi dua hari dan pada siklus sitostatistika ke-2 menjadi dua setengah hari, dari median durasi neutropenia grade 4 dan grade 3 tanpa G-CSF, yaitu empat dan lima hari berurutan. Febrile neutropenia ditemukan pada 7 pasien yang mendapat rhG-CSF produksi Asia (24.1%), lebih rendah jika dibandingkan studi tanpa rhG-CFS (31.3-34% FN). Tiga pasien mendapat rhG-CSF produksi Asia (10,3%) dirawat inap akibat febrile neutropenia, lebih rendah jika dibandingkan rawat inap pada studi tanpa rhG-CSF (24-28%). Kejadian yang tidak diinginkan terbanyak adalah mual dan muntah yang terjadi pada 9 (31%) pasien. Sebagai kesimpulan, penggunaan rhG-CSF produksi Asia untuk profilaksis primer pada pasien LNH usia lanjut yang mendapat regimen CHOP dapat mengurangi durasi neutropenia, mengurangi kejadian febrile neutropenia, dan angka rawat inap akibat febrile neutropenia.Kata kunci : Efektivitas, keamanan, G-CSF, LNH pada usia lanjut
Preoperative Neoadjuvant Hormonal Therapy and Neoadjuvant Chemotherapy for Stage 3B and 4 Breast Cancer Patients in Dharmais Hospital-National Cancer Center, Indonesia: A Cohort Study Karsono, Ramadhan; Purwanto, Denni Joko; Haryono, Samuel J.; Karsono, Bambang; Sari, Lenny; Pratiwi, Yulia; Aryandono, Teguh
Indonesian Journal of Cancer Vol 12, No 4 (2018): October-December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (891.03 KB) | DOI: 10.33371/ijoc.v12i4.604

Abstract

Background: There are no data of efficacy comparison between primary systemic therapy in stage 3B and 4 breast cancer patients in Indonesia. This study compared long term outcomes of breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)Methods: This was a cohort study conducted from 2011 to 2017. A total of 122 patients with stage 3B and 4 breast cancer received NAHT (n = 62) or NACT (n = 60) within a 6 cycles for NACT and 6 months for NAHT were included. Patients were excluded if they had a mastectomy before treatment, were pregnant, had been given hormonal therapy or chemotherapy before, had a contra-indication of chemotherapy, had a contra-indication of salpingo-oophorectomy bilateral for premenopausal patients, and declined to enter this study. The primary outcome of this study was overall survival. The outcomes were analysed using Kaplan-Meier for survival analysis and cox proportional hazard regression to estimate the hazard ratio.Results: There was a statistically significant difference in overall survival (p = 0.038). Median overall survival for NAHT patients was 1265 days and for NACT patients was 654 days. The hazard ratio showed NACT patients had a higher risk than NAHT patients (1.7 95% CI 1.03 – 2.9). Pathological complete response rate was higher in the NACT group than in the NAHT group (3.3% vs. 0%).Conclusions: Neoadjuvant hormonal therapy was superior to neoadjuvant chemotherapy in term of overall survival.
Co-Authors A, Hendra Abidin Widjanarko Ahmad Padhil Aiyub, Hendra Andriana, Dela Aru W. Sudoyo Asrul Harsal, Asrul Atmoko, Dwi Azhar Azhar Azmah Fithri, Cut Deni Deni DENNI JOKO PURWANTO, DENNI JOKO Djumhana Atmakusuma, Djumhana Dody Ranuhardy, Dody Eiji Tatsumi Eri Saputra Fidyati Fidyati, Fidyati Foenna, Fala Harryanto Reksodiputro, Harryanto Haryono, Samuel J. Hendra Hendra HILMAN TADJOEDIN, HILMAN Hiroki Yabe Humaro, Raihan Junianti, Emmy Kaho Furuta Karmel L. Tambunan Karsono, Ramadhan Kartika W. Taroeno-Hariadi Ken-Ichi Nagai Lenny Sari, Lenny Liana, Indah Lonarissa Harditya Putri, Vandika Nadia Luthfi, Irsanuddin Maghfira Maharani, Ayunda Mangkupradja, Didi Rochyadi Manurung, Gerson Mardiah S. Hardianti Meilani Syampurnawati Mirsa, Rinaldi Nadia Farhanah Syafhan Noorwati S -, Noorwati S Nugroho Prayogo Olivia, Sisca P, A. Dwi Wahyuni Pasaribu, Suci Untari Putri Handayani Pulungan, Dara Nabila Putra, Muhammad Sandi Rachman, Faizal Rachmat Pramukty Rekha Putri, Khana Ronald Hukom Safyan, Adi Shufrie Effendi, Shufrie Sri Wulandari Syafrizal Syafei, Syafrizal Syafwandi, Syafwandi Syauket , Amalia Syauket, Amalia Takayuki Ishikawa Takayuki Takahashi Taufiq Immawan, Taufiq Teguh Aryandono Tri Widyastuti Yahdiana Harahap Yayan Hendayana Yuji Kishimoto Yulia Pratiwi Zakifman Jack, Zakifman Zubairi Djoerban